Prevention of HIV Infection Among Injection Drug Users in Resource-limited Settings

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Apr 20

PMID 20397939

Citations 40

Authors

David Vlahov

Angela M Robertson

Steffanie A Strathdee

Affiliations

Soon will be listed here.

Abstract

Injection drug use contributes to considerable global morbidity and mortality associated with human immunodeficiency virus (HIV) infection and AIDS and other infections due to blood-borne pathogens through the direct sharing of needles, syringes, and other injection equipment. Of approximately 16 million injection drug users (IDUs) worldwide, an estimated 3 million are HIV infected. The prevalence of HIV infection among IDUs is high in many countries in Asia and eastern Europe and could exacerbate the HIV epidemic in sub-Saharan Africa. This review summarizes important components of a comprehensive program for prevention of HIV infection in IDUs, including unrestricted legal access to sterile syringes through needle exchange programs and enhanced pharmacy services, treatment for opioid dependence (ie, methadone and buprenorphine treatment), behavioral interventions, and identification and treatment of noninjection drug and alcohol use, which accounts for increased sexual transmission of HIV. Evidence supports the effectiveness of harm-reduction programs over punitive drug-control policies.

Citing Articles

Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.

Biondi B, Vander Wyk B, Schlossberg E, Shaw A, Springer S Addict Sci Clin Pract. 2022; 17(1):15.

PMID: 35255967 PMC: 8899775. DOI: 10.1186/s13722-022-00299-1.

Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: A qualitative study exploring challenges and mitigating strategies.

Childs E, Biello K, Valente P, Salhaney P, Biancarelli D, Olson J Int J Drug Policy. 2020; 90:103080.

PMID: 33340947 PMC: 8046716. DOI: 10.1016/j.drugpo.2020.103080.

Effectiveness of interventions for changing HIV related risk behaviours among key populations in low-income setting: A Meta-Analysis, 2001-2016.

Deuba K, Sapkota D, Shrestha U, Shrestha R, Rawal B, Badal K Sci Rep. 2020; 10(1):2197.

PMID: 32041979 PMC: 7010789. DOI: 10.1038/s41598-020-58767-0.

Utilizing social media to explore overdose and HIV/HCV risk behaviors among current opioid misusers.

Cavazos-Rehg P, Grucza R, Krauss M, Smarsh A, Anako N, Kasson E Drug Alcohol Depend. 2019; 205:107690.

PMID: 31778902 PMC: 6894427. DOI: 10.1016/j.drugalcdep.2019.107690.

The syndemic effect of HIV/HCV co-infection and mental health disorders on acute care hospitalization rate among people living with HIV/AIDS: a population-based retrospective cohort study.

St-Jean M, Tafessu H, Closson K, Patterson T, Lavergne M, Elefante J Can J Public Health. 2019; 110(6):779-791.

PMID: 31441005 PMC: 6964491. DOI: 10.17269/s41997-019-00253-w.

References

Dewhurst J . Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. AIDS Care. 2016; 22(3):397. DOI: 10.1080/09540120903193757. View

Strathdee S, Celentano D, Shah N, Lyles C, Stambolis V, Macalino G . Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health. 1999; 76(4):448-60. PMC: 3456698. DOI: 10.1007/BF02351502. View

Krupitsky E, Zvartau E, Masalov D, Tsoy M, Burakov A, Egorova V . Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat. 2006; 31(4):319-28. DOI: 10.1016/j.jsat.2006.05.005. View

Sullivan L, Moore B, Chawarski M, Pantalon M, Barry D, OConnor P . Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2007; 35(1):87-92. PMC: 2587397. DOI: 10.1016/j.jsat.2007.08.004. View

Ellis R, Childers M, Cherner M, Lazzaretto D, Letendre S, Grant I . Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003; 188(12):1820-6. DOI: 10.1086/379894. View

Morison L, Buve A, Zekeng L, Heyndrickx L, Anagonou S, Musonda R . HIV-1 subtypes and the HIV epidemics in four cities in sub-Saharan Africa. AIDS. 2001; 15 Suppl 4:S109-16. DOI: 10.1097/00002030-200108004-00012. View

Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh D . The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment. J Urban Health. 2008; 85(6):812-25. PMC: 2587648. DOI: 10.1007/s11524-008-9312-9. View

Latkin C, Donnell D, Metzger D, Sherman S, Aramrattna A, Davis-Vogel A . The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. Soc Sci Med. 2008; 68(4):740-8. PMC: 2724962. DOI: 10.1016/j.socscimed.2008.11.019. View

Strathdee S, Zafar T, Brahmbhatt H, Baksh A, ul Hassan S . Rise in needle sharing among injection drug users in Pakistan during the Afghanistan war. Drug Alcohol Depend. 2003; 71(1):17-24. DOI: 10.1016/s0376-8716(03)00072-3. View

10.

Odutolu O . Convergence of behaviour change models for AIDS risk reduction in sub-Saharan Africa. Int J Health Plann Manage. 2005; 20(3):239-52. DOI: 10.1002/hpm.812. View

11.

Monterroso E, Hamburger M, Vlahov D, Des Jarlais D, Ouellet L, Altice F . Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). J Acquir Immune Defic Syndr. 2000; 25(1):63-70. DOI: 10.1097/00042560-200009010-00009. View

12.

Buve A, Bishikwabo-Nsarhaza K, Mutangadura G . The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet. 2002; 359(9322):2011-7. DOI: 10.1016/S0140-6736(02)08823-2. View

13.

Dorabjee , Samson . A multi-centre rapid assessment of injecting drug use in India. Int J Drug Policy. 2000; 11(1-2):99-112. DOI: 10.1016/s0955-3959(99)00058-4. View

14.

Dolan K, Rutter S, Wodak A . Prison-based syringe exchange programmes: a review of international research and development. Addiction. 2003; 98(2):153-8. DOI: 10.1046/j.1360-0443.2003.00309.x. View

15.

Sorensen J, Copeland A . Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000; 59(1):17-31. DOI: 10.1016/s0376-8716(99)00104-0. View

16.

Schechter M, Strathdee S, Cornelisse P, Currie S, Patrick D, Rekart M . Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS. 1999; 13(6):F45-51. DOI: 10.1097/00002030-199904160-00002. View

17.

Mausbach B, Semple S, Strathdee S, Zians J, Patterson T . Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-negative, heterosexual methamphetamine users: results from the Fast-Lane Study. Ann Behav Med. 2007; 34(3):263-74. DOI: 10.1007/BF02874551. View

18.

Carrieri M, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B . Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend. 2000; 60(1):51-4. DOI: 10.1016/s0376-8716(99)00136-2. View

19.

Purcell D, Metsch L, Latka M, Santibanez S, Gomez C, Eldred L . Interventions for seropositive injectors-research and evaluation: an integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. J Acquir Immune Defic Syndr. 2004; 37 Suppl 2:S110-8. DOI: 10.1097/01.qai.0000140609.44016.c4. View

20.

Abdala N, Stephens P, Griffith B, Heimer R . Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20(1):73-80. DOI: 10.1097/00042560-199901010-00011. View